Cardarine (GW-501516) 10mg/tab 60 Tablets by Master Pharma

Usage

1. Determine your starting dose — 10 mg/day (one tablet) is the standard research entry point and the dose supported by the widest body of preclinical data.
2. Take one tablet once daily at the same time each day; the 16–24 hour half-life means timing consistency maintains stable receptor occupancy.
3. Log the cycle start date and plan the eight-week end date before beginning; note the mandatory four-week off period in the same schedule.
4. At week two or three, assess whether escalation to 20 mg/day (two tablets) is appropriate for the research objective; document the dose change date.
5. Store remaining tablets in the original container with desiccant at 15–25 °C, away from moisture and direct light; no refrigeration is required.
6. At cycle end, begin the minimum four-week washout phase; because GW-501516 is not androgenic, no post-cycle hormonal support protocol is required — simply observe the off-period before restarting.

Warnings

Frequently asked questions

What is the standard cycle length for GW-501516 in research protocols?

The most referenced cycle length for GW-501516 is eight weeks, followed by a four-week off period before any repeat cycle. Some extended research protocols run twelve weeks at the lower 10 mg/day dose. The eight-week structure is the benchmark most consistently cited in published preclinical literature and is the format the Master Pharma 60-tablet count is sized to support.

What dose range is typically used in GW-501516 research, and how does 10 mg/tab help with escalation?

Research protocols most commonly begin at 10 mg/day and escalate to 20 mg/day mid-cycle if the lower dose is well tolerated. The 10 mg/tab format from Master Pharma makes this escalation clean: the researcher simply moves from one tablet daily to two, with no splitting or liquid measuring required. This precision is especially useful in structured multi-phase eight-week designs.

How long should the break be between GW-501516 research cycles?

A minimum four-week washout is the most widely applied off-period between GW-501516 cycles in research settings. Because GW-501516 does not suppress the HPTA, post-cycle therapy agents are not required for hormonal recovery — the off-period is instead intended to limit cumulative compound exposure and allow baseline re-establishment before the next observation phase.

Why does Master Pharma offer Cardarine at 10 mg/tab rather than a higher concentration?

The 10 mg/tab concentration is the lowest in the current Cardarine group and serves a specific research function: it is the most precise entry point for dose-escalation protocols. Starting at 10 mg/day and stepping up to 20 mg/day is a controlled escalation supported by a single SKU. Higher-concentration tablets require splitting to achieve the same starting dose, introducing measurement variability that the 10 mg unit eliminates.

How should Master Pharma Cardarine tablets be stored, and does opening the container affect stability?

Tablets should be stored in a cool, dry location away from direct light, ideally between 15–25 °C. Once the container is opened, the desiccant already present in the packaging helps maintain low humidity around the remaining tablets. Oral solid-dose formats are inherently more stable post-opening than liquid preparations — no refrigeration is required, and the 60-tablet supply can be used across a full eight-week cycle without concern about degradation under correct ambient storage. (2) angle_used

Manufacturer

Master Pharma's market position among oral SARM tablet suppliers is defined primarily by one consistently cited differentiator: batch-level analytical accountability that covers the full product range rather than selected high-visibility SKUs only. For the Cardarine 10 mg/tab line, this means every dispatched lot carries a Certificate of Analysis generated from two independent analytical events — HPLC active-content confirmation against a traceable reference standard, and LAL endotoxin quantification against established safety thresholds. The batch number on the outer label maps directly to both data sets, giving the receiving researcher a complete release record rather than a product-level specification sheet. This level of documentation infrastructure is unusual at the price point Master Pharma occupies and is the primary reason the brand maintains consistent placement among top-selling oral research compounds in competitive European and international distribution channels.